Online inquiry

IVTScrip™ mRNA-Human ACTR3C, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK8874MR)

This product GTTS-WK8874MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ACTR3C protein. This product can be used in Regulatory T (Treg) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001164458.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 653857
UniProt ID Q9C0K3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACTR3C, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK8874MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK21598MR IVTScrip™ mRNA-Human APBB1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APBB1
GTTS-WK12160MR IVTScrip™ mRNA-Human ACTG2, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACTG2
GTTS-WK16762MR IVTScrip™ mRNA-Human ANXA4, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANXA4
GTTS-WK27495MR IVTScrip™ mRNA-Human ASB13, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASB13
GTTS-WK25996MR IVTScrip™ mRNA-Human ASB15, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASB15
GTTS-WK23804MR IVTScrip™ mRNA-Human ARHGDIA, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARHGDIA
GTTS-WK7399MR IVTScrip™ mRNA-Human ADAMTS14, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADAMTS14
GTTS-WK28710MR IVTScrip™ mRNA-Human ASGR1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASGR1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW